LP 143
Alternative Names: AN143; LP143Latest Information Update: 16 Mar 2022
At a glance
- Originator Longboard Pharmaceuticals
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 03 Mar 2022 Longboard Pharmaceuticals plans clinical trials for LP 143
- 01 Feb 2022 Longboard Pharmaceuticals has patent protection for LP 143 in USA, China, Japan, Canada, India, Eurasia (9 countries), South Korea, Australia, Mexico, Taiwan, New Zealand, Lebanon, Israel, and Macao
- 01 Feb 2022 Longboard Pharmaceuticals has patents pending for LP 143 in USA, Japan, Brazil, South Korea, GCC, Argentina, Bangladesh, Hong Kong, Singapore and Venezuela